Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.38 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 4/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945662 | 0.95 | EPHX2 (0.39) | EPHX2USP28USP25MAOAMAOB | |
| SCHEMBL30469444 | 0.83 | EPHX2 (0.43) | EPHX2USP28USP25MAOAMAOB | |
| SCHEMBL211400 | 0.83 | EPHX2 (0.43) | EPHX2USP28USP25MAOAMAOB | |
| SCHEMBL18085147 | 0.82 | TSHR (0.40) | EPHX2ALPLADRA2AMCHR1NPY5R | |
| SCHEMBL30294097 | 0.82 | TSHR (0.40) | EPHX2ALPLADRA2AMCHR1NPY5R | |
| SCHEMBL20563265 | 0.81 | HTR2A (0.41) | EPHX2MAOAMAOBALPLADRA2A | |
| SCHEMBL4140867 | 0.81 | EPHX2 (0.38) | EPHX2USP28USP25MAOAMAOB | |
| SCHEMBL3940950 | 0.79 | EPHX2 (0.43) | EPHX2MAOAMAOBPTPN1FFAR4 | |
| SCHEMBL211296 | 0.78 | EPHX2 (0.41) | EPHX2USP28USP25MAOAMAOB | |
| SCHEMBL29555215 | 0.78 | EPHX2 (0.41) | EPHX2USP28USP25MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1432693-A2 | MCH RECEPTOR ANTAGONISTS | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028641-A2 | MCH RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | EPHX2 3412/4885USP28 3149/4885USP25 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.